BE Biosol, Gates Foundation ink pact for anaemia injection FCM

The agreement is for development of Ferric Carboxymaltose (FCM) injection and to improve accessibility of the drug in multiple countries.
BE Biosol, the CDMO arm of vaccine maker Biological E., has entered into an agreement with the Gates Foundation for development of Ferric Carboxymaltose (FCM) injection and to improve accessibility of the drug to treat iron deficiency anaemia in multiple countries.
The Gates Foundation will support BE Biosol for scale-up and clinical development of the product for the target markets. BE Biosol will leverage its research and development capabilities and manufacturing infrastructure to support the programme, the company said in a release on the agreement to expand access to FCM injection in Africa.
BE Biosol aims to establish a differentiated, cost-competitive offering and build a meaningful presence in the markets by leveraging its manufacturing scale and proprietary API technology. The collaboration with the Gates Foundation reflects confidence in BE Biosol’s capabilities to develop and manufacture technologically demanding sterile formulations at competitive costs and scale. More broadly, it reinforces the company’s strategy to establish itself as a globally competitive CDMO platform across complex biologics and pharmaceutical modalities, said Narender Mantena, Managing Director.
BE Biosol’s manufacturing facility is in Shamirpet, Telangana. Since its commissioning in 2018 it has undergone multiple inspections and received approvals multiple times from leading regulatory agencies, including the U.S. FDA, Infarmed (Portugal), the UK MHRA and Brazil’s ANVISA, the company said in a release.
- biosol
- gates
- foundation
- ink
- pact
- anaemia
- injection
- fcm


